Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mg
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Hypercholesterolemia
Conditions
Hypercholesterolemia
Trial Timeline
Dec 1, 2011 → Oct 1, 2013
NCT ID
NCT01660191About Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mg
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mg is a approved stage product being developed by Eli Lilly for Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01660191. Target conditions include Hypercholesterolemia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01660191 | Approved | Completed |
Competing Products
20 competing products in Hypercholesterolemia